Search
Search Results
-
Evaluation of Homologous Recombination Deficiency in Ovarian Cancer
Homologous recombination deficiency (HRD) is an important biomarker guiding selection of ovarian cancer patients who will derive the most benefit...
-
A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency
E7820 and Indisulam (E7070) are sulfonamide molecular glues that modulate RNA splicing by degrading the splicing factor RBM39 via ternary complex...
-
Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration
There is emerging evidence about the predictive role of homologous recombination deficiency (HRD), but this is less defined in gastrointestinal (GI)...
-
Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape
Purpose of ReviewHomologous recombination repair deficiency (HRD) increases breast cancer susceptibility and influences both prophylactic and active...
-
Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer
Homologous recombination DNA-repair deficiency (HRD) is a common driver of genomic instability and confers a therapeutic vulnerability in cancer. The...
-
Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial
The bevacizumab (bev)/olaparib (ola) maintenance regimen was approved for BRCA1/2 -mutated (BRCAmut) and Homologous Recombination Deficient (HRD)...
-
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes
PurposeA 3-biomarker homologous recombination deficiency (HRD) score is a key component of a currently FDA-approved companion diagnostic assay to...
-
Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
BackgroundHomologous Recombination Deficiency (HRD) is a predictive biomarker for ovarian cancer treated with PARP inhibitors or for breast cancer...
-
Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests
Germline BRCA1/2 mutation status is predictive for response to Poly-[ADP-Ribose]-Polymerase (PARP) inhibitors in breast cancer (BC) patients....
-
A Multiomics Signature Highlights Alterations Underlying Homologous Recombination Deficiency in Triple-Negative Breast Cancer
BackgroundHomologous recombination (HR) is a key pathway in DNA double-strand damage repair. HR deficiency (HRD) occurs more commonly in...
-
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
PARP inhibitors were recently approved for treatment of molecularly-defined subsets of metastatic castrate-resistant prostate cancer (mCRPC)...
-
Human papillomavirus E7 protein induces homologous recombination defects and PARPi sensitivity
PurposeCervical cancer is a common gynecological malignancy, pathologically associated with persistent infection of high-risk types of human...
-
A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations
Deleterious mutations in the BRCA1 and BRCA2 genes have significant therapeutic relevance in clinical settings regarding personalized therapy...
-
Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value
Despite advances in our understanding of the molecular landscape of prostate cancer and the development of novel biomarker-driven therapies, the...
-
Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)
BackgroundIntraductal carcinoma of the prostate (IDC-P) is a subtype of prostate cancer featured by poor prognosis. Previous studies suggested IDC-P...
-
Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database Study
IntroductionDefects in the homologous recombination repair (HRR) pathway can include mutations in BRCA1 and BRCA2 (BRCAm) and other HRR genes...
-
Targeting DDX11 promotes PARP inhibitor sensitivity in hepatocellular carcinoma by attenuating BRCA2-RAD51 mediated homologous recombination
Homologous recombination (HR) is a major DNA double-strand break (DSB) repair pathway of clinical interest because of treatment with poly(ADP-ribose)...
-
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
BackgroundIn the PAOLA-1 trial, olaparib plus bevacizumab demonstrated significant clinical benefit following partial or complete response to...
-
Challenges of diagnosing homologous recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution
PurposeWe evaluated the prevalence of homologous recombination deficiencies (HRD) to determine the efficacy of different techniques and clinical...
